EMA Authorised: Zolsketil pegylated liposomal (doxorubicin hydrochloride, liposomal) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised Zolsketil pegylated liposomal doxorubicin for ovarian cancer, Kaposi sarcoma, and multiple myeloma. The Marketing Authorization Holder is Acc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kaposi Sarcoma
• Multiple Myeloma
• Ovarian Cancer

Drugs mentioned

• Zolsketil pegylated liposomal doxorubicin (doxorubicin hydrochloride, liposomal)

Snippet

Status: Authorised. Therapeutic area: Ovarian Neoplasms;Sarcoma, Kaposi;Multiple Myeloma. MAH: Accord Healthcare S.L.U.. Decision date: 15/04/2026